Latest Conference Articles

Sheldon Litwin, MD, a cardiologist at the Medical University of South Carolina, discussed the significant recent advances in anti-obesity drugs.

Donna Ryan, MD, discussed her presentation about pharmacological approaches for obesity, which patients they are indicated for, and considerations for pharmacists.

The 2022 American Heart Association, American College of Cardiology, and Heart Failure Society of America guidelines recommend SGLT2 inhibitors for nearly all patients in cardiovascular practice.

Pharmacists play a vital role in ensuring that patients can afford their medications, either by advising them on more affordable options or working with insurers and prescribers to find cheaper alternatives.

Although scientists have long been working on anti-obesity medications, several key failures in recent decades have made this a challenge.

Because of the complexities of cardio-oncology medication regimens, pharmacists are vital to assess drug-drug interactions using multiple resources, such as databases, case reports, FDA and National Institutes of Health guidelines, and package inserts.

Findings from the AFFIRM trial found increased risks after stopping oral anticoagulant therapy after rhythm control, and the same is true for stopping treatment with oral anticoagulants after successful ablation.

In an interview with Pharmacy Times, Anastasia Armbruster, PharmD, FACC, BCCP, discussed her presentation at the American College of Cardiology 2023 Scientific Session.

Although pharmacokinetics and dynamics can be complex, particularly in patients with cancer, pharmacists play a key role in the various considerations and treatment decisions.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Health care providers can manage “fake news” about statins, including their indications and misinformation regarding liver and kidney damage.

Bempedoic acid is indicated as an adjunct to diet and maximally tolerated statin therapy for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein-cholesterol.

In addition to the hundreds of sessions and events, ACC has partnered with the World Heart Federation, bringing an international focus to the meeting.

Patients with atherosclerotic cardiovascular disease who were already receiving statin therapy had a reduction in adverse cardiovascular outcomes with earlier initiation of evolocumab.

American College of Cardiology President Edward Fry, MD, FACC, discussed what attendees can look forward to at the 2023 Scientific Sessions.

The inaugural Oncology Pharmacists Connect is directed toward pharmacists practicing in oncology in multiple practice environments.

Positive data on the novel prostate cancer combination treatment was presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

Olaparib with abiraterone increased survival in patients with metastatic prostate cancer compared to the current standard of care, according to a session at the ASCO Genitourinary Cancers Symposium.

The FDA approved darolutamide in 2019 for the treatment of patients with nonmetastatic castration-resistant prostate cancer based improved metastasis-free survival.

New data identifying a particular gene expression signature will be presented at the 2023 ASCO Genitourinary Symposium.

Specialty medication has grown to about 55% of net spending, which is up by 28% since 2011 mostly driven by autoimmune diseases and oncology.

Biosimilars, staffing issues, and mail-order companies are key trends to watch.

Social media can leverage pharmacists as personalities and help influence which topics the public discusses and the data they consume, presenter says.

Anthony Pudlo, PharmD, MBA, executive director of the Tennessee Pharmacists Association, discussed his presentation at the National Association of Chain Drug Stores (NACDS) 2023 Regional Chain conference.

Pudlo’s presentation focused on key shifts in chain pharmacies, including pharmacy benefit manager (PBM) reform, pharmacist-administered vaccine trends, and provider status.

Comprehensive medication management is 1 way to optimize therapy, according to Steven Chen, PharmD, FASHP, FCSHP, FNAP, who spoke at the NACDS Regional 2023 Meeting.

National Association of Chain Drug Stores CEO and president, and 2 other experts discuss the importance of advocacy on the statewide policy level.

With the growing importance of pharmacy services, Chen said pharmacists should think outside the box and get creative when finding effective payment models.